Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pipeline Of Alzheimer's Drugs Targeting Amyloid-Beta Protein

You may also be interested in...



Amyvid Approval Just The Start Of A Critical Year For Alzheimer’s

One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.

Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle

Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.

FDA Relaxes Safety Requirements For Alzheimer's Trials, But Uncertainty Persists

Sponsors and contract research organizations expressed cautious optimism about FDA's adoption of some of the recommendations of the Alzheimer's Association Research Roundtable Workgroup, but the agency isn't specifying which recommendations it is accepting.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel